This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (100)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Murat V. Kalayoglu, MD, PhD; Peter Libby, MD; Gerald I. Byrne, PhD

JAMA. 2002;288:2724-2731.

Recent appreciation of atherosclerosis as a chronic, inflammatory disease has rekindled efforts to examine the role that infectious agents may play in atherogenesis. In particular, much interest has focused on infection with Chlamydia pneumoniae. The possibility that a prokaryote contributes to atherogenesis has high clinical interest, as C pneumoniae infection may be a treatable risk factor. To review the evidence implicating C pneumoniae in the pathogenesis of atherosclerosis, we searched MEDLINE for articles published between January 1966 and October 2002 on the association of C pneumoniae and atherosclerosis. We also used online resources, texts, meeting abstracts, and expert opinion. We included 5 types of studies (epidemiological, pathology based, animal model, cell biology, and human antibiotic treatment trials) and extracted diagnostic, pathophysiologic, and therapeutic information from the selected literature; consensus was reached on interpretation discrepancies. Chlamydia pneumoniae is associated with atherosclerosis by epidemiological and pathology-based studies. Animal model and cell biology studies suggest that the pathogen can modulate atheroma biology, including lipid- and inflammatory-related processes. Although some preliminary antibiotic treatment trials in patients with coronary artery disease indicated a reduction in recurrent coronary events, larger studies have not shown benefits in individuals with stable coronary artery disease. It is unlikely that C pneumoniae infection is necessary to initiate atherosclerosis. Furthermore, conventional antibiotic therapy may not eradicate the organism or reduce mortality in individuals with atherosclerotic vascular disease. Nevertheless, the current body of evidence establishes this pathogen as a plausible, potentially modifiable risk factor in cardiovascular disease.

Author Affiliations: Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School (Dr Kalayoglu) and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital (Dr Libby), Boston, Mass; and Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis (Dr Byrne).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chlamydia pneumoniae seropositivity in aetiological subtypes of brain infarction and carotid atherosclerosis: a case control study
Alamowitch et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:147-151.
ABSTRACT | FULL TEXT  

The Proinflammatory Cytokine Response to Chlamydia trachomatis Elementary Bodies in Human Macrophages Is Partly Mediated by a Lipoprotein, the Macrophage Infectivity Potentiator, through TLR2/TLR1/TLR6 and CD14
Bas et al.
J. Immunol. 2008;180:1158-1168.
ABSTRACT | FULL TEXT  

Atherosclerosis Pathophysiology and the Role of Novel Risk Factors: A Clinicobiochemical Perspective
Mallika et al.
ANGIOLOGY 2007;58:513-522.
ABSTRACT  

The p47 GTPases Iigp2 and Irgb10 Regulate Innate Immunity and Inflammation to Murine Chlamydia psittaci Infection
Miyairi et al.
J. Immunol. 2007;179:1814-1824.
ABSTRACT | FULL TEXT  

Molecular Characterization and Subcellular Localization of Macrophage Infectivity Potentiator, a Chlamydia trachomatis Lipoprotein
Neff et al.
J. Bacteriol. 2007;189:4739-4748.
ABSTRACT | FULL TEXT  

Persistent Chlamydia pneumoniae Infection of Cardiomyocytes Is Correlated with Fatal Myocardial Infarction
Spagnoli et al.
Am. J. Pathol. 2007;170:33-42.
ABSTRACT | FULL TEXT  

Chlamydia pneumoniae in foci of "early" calcification of the tunica media in arteriosclerotic arteries: an incidental presence?
Bobryshev et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;290:H1510-H1519.
ABSTRACT | FULL TEXT  

Correlation Between Chlamydia pneumoniae Detection From Coronary Angioplasty Balloons and Atherosclerosis Severity
Wyplosz et al.
J Am Coll Cardiol 2006;47:1229-1231.
FULL TEXT  

Bacterial Lipopolysaccharide Enhances Cardiac Dysfunction but Not Retroviral Replication in Murine AIDS: Roles of Macrophage Infiltration and Toll-Like Receptor 4 Expression
Chaves et al.
Am. J. Pathol. 2006;168:727-735.
ABSTRACT | FULL TEXT  

Seropositivity to Chlamydia pneumoniae Is Associated With Risk of First Ischemic Stroke
Elkind et al.
Stroke 2006;37:790-795.
ABSTRACT | FULL TEXT  

Chlamydia pneumoniae Burden in Carotid Arteries Is Associated With Upregulation of Plaque Interleukin-6 and Elevated C-Reactive Protein in Serum
Johnston et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:2648-2653.
ABSTRACT | FULL TEXT  

Chlamydophila pneumoniae and Mycoplasma pneumoniae: A Role in Asthma Pathogenesis?
Johnston and Martin
Am. J. Respir. Crit. Care Med. 2005;172:1078-1089.
ABSTRACT | FULL TEXT  

Chlamydophilapneumoniae and Mycoplasma pneumoniae in respiratory specimens of children with chronic lung diseases
Teig et al.
Thorax 2005;60:962-966.
ABSTRACT | FULL TEXT  

Effects of Repeated Chlamydia pneumoniae Inoculations on Aortic Lipid Accumulation and Inflammatory Response in C57BL/6J Mice
Tormakangas et al.
Infect. Immun. 2005;73:6458-6466.
ABSTRACT | FULL TEXT  

Porphyromonas gingivalis Fimbria-Dependent Activation of Inflammatory Genes in Human Aortic Endothelial Cells
Chou et al.
Infect. Immun. 2005;73:5367-5378.
ABSTRACT | FULL TEXT  

Relative elevation in baseline leukocyte count predicts first cerebral infarction
Elkind et al.
Neurology 2005;64:2121-2125.
ABSTRACT | FULL TEXT  

Effects of Antibiotic Therapy on Outcomes of Patients With Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials
Andraws et al.
JAMA 2005;293:2641-2647.
ABSTRACT | FULL TEXT  

Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson
NEJM 2005;352:1685-1695.
FULL TEXT  

Chlamydia pneumoniae and Lung Cancer: Epidemiologic Evidence
Littman et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:773-778.
ABSTRACT | FULL TEXT  

Effect of Clarithromycin Treatment on Chlamydia pneumoniae in Vascular Tissue of Patients with Coronary Artery Disease: a Randomized, Double-Blind, Placebo-Controlled Trial
Berg et al.
J. Clin. Microbiol. 2005;43:1325-1329.
ABSTRACT | FULL TEXT  

Giant cell arteritis and cardiovascular disease in older adults
Ray et al.
Heart 2005;91:324-328.
ABSTRACT | FULL TEXT  

Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo
Rupp et al.
Proc. Natl. Acad. Sci. USA 2005;102:3447-3452.
ABSTRACT | FULL TEXT  

Asymptomatic Carotid Atherosclerosis Is Associated With Circulating Chlamydia pneumoniae DNA in Younger Normotensive Subjects in a General Population Survey
Mitusch et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:386-391.
ABSTRACT | FULL TEXT  

Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research
de Kruif et al.
Cardiovasc Res 2005;65:317-327.
ABSTRACT | FULL TEXT  

Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases
Voils et al.
The Annals of Pharmacotherapy 2005;39:86-94.
ABSTRACT | FULL TEXT  

Potential Role of Endotoxin as a Proinflammatory Mediator of Atherosclerosis
Stoll et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:2227-2236.
ABSTRACT | FULL TEXT  

Chlamydial infection and progression of carotid atherosclerosis in patients on regular haemodialysis
Kato et al.
Nephrol Dial Transplant 2004;19:2539-2546.
ABSTRACT | FULL TEXT  

Oxidized Low Density Lipoprotein Blocks Lipopolysaccharide-induced Interferon {beta} Synthesis in Human Macrophages by Interfering with IRF3 Activation
Marson et al.
J. Biol. Chem. 2004;279:28781-28788.
ABSTRACT | FULL TEXT  

Comparison of Quantitative and Semiquantitative Enzyme-Linked Immunosorbent Assays for Immunoglobulin G against Chlamydophila pneumoniae to a Microimmunofluorescence Test for Use with Patients with Respiratory Tract Infections
Hermann et al.
J. Clin. Microbiol. 2004;42:2476-2479.
ABSTRACT | FULL TEXT  

Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology
Faxon et al.
Circulation 2004;109:2617-2625.
FULL TEXT  

Heat-Shock Protein 60-Reactive CD4+CD28null T Cells in Patients With Acute Coronary Syndromes
Zal et al.
Circulation 2004;109:1230-1235.
ABSTRACT | FULL TEXT  

Activation of Raf/MEK/ERK/cPLA2 Signaling Pathway Is Essential for Chlamydial Acquisition of Host Glycerophospholipids
Su et al.
J. Biol. Chem. 2004;279:9409-9416.
ABSTRACT | FULL TEXT  

Chlamydia trachomatis and Chlamydia pneumoniae Infections in Children and Adolescents
Hammerschlag
Pediatr. Rev. 2004;25:43-51.
FULL TEXT  

Antibiotic Therapy for Coronary Artery Disease: Can a WIZARD Change It All?
Pislaru and Van de Werf
JAMA 2003;290:1515-1516.
FULL TEXT  

Chlamydia uncloaked
Byrne
Proc. Natl. Acad. Sci. USA 2003;100:8040-8042.
FULL TEXT  

Chlamydia pneumoniae, Antibiotic Treatment, and Early Atherosclerosis * Response
Liuba et al.
Circulation 2003;107:e205-205.
FULL TEXT  

Involvement of Nicotinic Acetylcholine Receptors in Controlling Chlamydiapneumoniae Growth in Epithelial HEp-2 Cells
Yamaguchi et al.
Infect. Immun. 2003;71:3645-3647.
ABSTRACT | FULL TEXT  

Prospects for the Medical Management of Abdominal Aortic Aneurysms
Steinmetz et al.
VASC ENDOVASCULAR SURG 2003;37:151-163.
ABSTRACT  

Is Chlamydia pneumoniae infection a risk factor for age related macular degeneration?
Ishida et al.
Br. J. Ophthalmol. 2003;87:523-524.
FULL TEXT  

Serological Association Between Chlamydia pneumoniae Infection and Age-Related Macular Degeneration
Kalayoglu et al.
Arch Ophthalmol 2003;121:478-482.
ABSTRACT | FULL TEXT